Clozapine vs Olanzapine/samidorphan (Qilu)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Clozapine
Marketed by HLS Therapeutics Inc.
NCT00250575 · Phase 3 · completed
The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.
Next expected readout: April 2027 · NCT04580134 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)
Result source: NCT03510325
Olanzapine/samidorphan (Qilu)
Developed by Qilu Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Clozapine | Olanzapine/samidorphan (Qilu) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00649844 | —Trial running · NCT06649214 |
| CGI-S, change | —Not posted · NCT00649844 | —Trial running · NCT06649214 |
| PANSS response | —Not posted · NCT00649844 | —Trial running · NCT06649214 |
| PSP, change | —Not posted · NCT00649844 | —Trial running · NCT06649214 |
| Relapse (% of patients) | —Not posted · NCT00649844 | —Trial running · NCT06649214 |
PANSS total, change
- Clozapine
- —Not posted · NCT00649844
- Olanzapine/samidorphan (Qilu)
- —Trial running · NCT06649214
CGI-S, change
- Clozapine
- —Not posted · NCT00649844
- Olanzapine/samidorphan (Qilu)
- —Trial running · NCT06649214
PANSS response
- Clozapine
- —Not posted · NCT00649844
- Olanzapine/samidorphan (Qilu)
- —Trial running · NCT06649214
PSP, change
- Clozapine
- —Not posted · NCT00649844
- Olanzapine/samidorphan (Qilu)
- —Trial running · NCT06649214
Relapse (% of patients)
- Clozapine
- —Not posted · NCT00649844
- Olanzapine/samidorphan (Qilu)
- —Trial running · NCT06649214
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Olanzapine/samidorphan (Qilu): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Clozapine: 3 of 4 rows · Olanzapine/samidorphan (Qilu): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Clozapine |
|---|---|
| Dropout rate | 41.7%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results0% NCT00498550 · Phase 4 · registry result, not featured evidence 17.2% NCT02404155 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results— NCT00498550 · Phase 4 · registry result, not featured evidence — NCT02404155 · Phase na · registry result, not featured evidence |
| Serious AEs | 13%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results26.7% NCT00498550 · Phase 4 · registry result, not featured evidence 6.9% NCT02404155 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a other-sialorrhea 43.5% weight gain 30.4% sedation 21.7% NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more resultsgastrointestinal disorder - other: hypersalivation 66.7% somnolence 60% weight gain 40% NCT00498550 · Phase 4 · registry result, not featured evidence salivation 68.2% sedation 52.9% malaise 52.6% NCT02404155 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Clozapine
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Olanzapine/samidorphan (Qilu)'s landscape